# Immunotherapy Study for Metastatic Renal Cell Cancer

> **NCT02035358** · PHASE1 · COMPLETED · sponsor: **NewLink Genetics Corporation** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Metastatic Clear-cell Renal Cancer
- Recurrent Renal Cell Carcinoma
- Refractory Renal Cell Carcinoma
- Metastatic Kidney Cancer

## Interventions

- **BIOLOGICAL:** HyperAcute®-Renal (HAR) Immunotherapy

## Key facts

- **NCT ID:** NCT02035358
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2017-01-03
- **Final completion:** 2021-01-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035358, "Immunotherapy Study for Metastatic Renal Cell Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02035358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*